Prospective observational study to investigate the long-term course of MR-guided percutaneous tumor ablation of primary or secondary liver or kidney tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026171

Enrollment

300

Registered

2021-08-23

Start date

2021-09-14

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22 C64

Interventions

Group 1: Patients undergoing a tumor ablation procedure as part of their treatment using one of the following (approved) techniques: Radiofrequency-, microwave-, lase-r or cryoablation, high-intensity

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: - Patients who have clinically indicated tumor ablation for primary or secondary liver or kidney tumors. - The indication for percutaneous tumor ablation takes place in an interdisciplinarytumor conference. - Completion of the age of 18 and the patient's legal capacity to give consent. - Concomitant diseases or adjuvant chemotherapy or previous therapy using transarterial chemotherapy or other ablation procedures do not constitute exclusion criteria for participation in the study.

Exclusion criteria

Exclusion criteria: - Missing or incomplete declaration of consent from the patient. - Minor patients. - Pregnant / breastfeeding women. - Patients incapable of giving consent.

Design outcomes

Primary

Measure	Time frame
Prospective data collection on 300 MR-guided tumor ablation procedures (with regard to the intervention and the "follow-up") and quality assurance.	—

Secondary

Measure	Time frame
- Assessment of the clinical benefit and effectiveness of different approved MR-guided tumor ablation procedures: - Thermoblation process: radio frequency, microwave, laser and Cryoablation and the high-intensity focused ultrasound, - Non-thermal tissue ablation method: irreversible electroporation. - Collection of data on overall survival, relapse-free survival, occurrence of local recurrences and complications. - Optimization of the intervention protocols with regard to possible time reduction. - Lesion-based evaluations using MRI. - Investigation of influencing factors on the therapy result and the development of local recurrences.	—

Measure

Time frame

- Assessment of the clinical benefit and effectiveness of different approved MR-guided tumor ablation procedures: - Thermoblation process: radio frequency, microwave, laser and Cryoablation and the high-intensity focused ultrasound, - Non-thermal tissue ablation method: irreversible electroporation. - Collection of data on overall survival, relapse-free survival, occurrence of local recurrences and complications. - Optimization of the intervention protocols with regard to possible time reduction. - Lesion-based evaluations using MRI. - Investigation of influencing factors on the therapy result and the development of local recurrences.

—

Countries

Germany

Contacts

Public ContactMoritz Winkelmann

Universitätsklinikum Tübingen, Radiologische Klinik, Abt. für Diagnostische & Interventionelle Radiologie

moritz.winkelmann@med.uni-tuebingen.de07071-2968527

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026